DDrare: Database of Drug Development for Rare Diseases

Searched query = "Osler disease", "Hereditary hemorrhagic telangiectasia", "Osler-Weber-Rendu disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = AVASTIN; AVASTIN 25 mg/ml - Konzentrat zur Herstellung einer Infusionsloesung; Acetate; Avastin; BEVACIZUMAB; Bevacizumab; Bevacuzimab spray; Blood samples; Chloride; Dicynone; Doxycycline; Doxycycline Hyclate; EMEA/H/C/000712; ETAMSYLATE; Estriol; Etamsylate; Ferrous sulphate 200mg oral tablet; Floseal; Gold; Itraconazole; Mupirocin; NINTEDANIB; NaCl; Nintedanib; Nintédanib; OCTREOTIDE; OCTREOTIDE ACETATE; OFEV; Octreotide; Octreotide LAR; Other: Epistaxis charts; Other: Packing; Other: Standard Treatment; Other: Standard care; PHYSIOLOGISCHE Kochsalzloesung Fresenius - Infusionsloesung; Pazopanib; Pegylated Interferon Alpha2b; Pomalidomide; Pomalidomide Oral Product; Propranolol; Propranolol treatment; RVG 18236; Ranibizumab; SODIUM CHLORIDE; SUB16402MIG; Sandostatin LAR; Sandostatin LAR 20 mg; Sclerotherapy; Sodium chloride; Soy protein isolate; Sporanox; Sterile saline; Submucosal Bevacizumab; THALIDOMIDE; THALIDOMIDE CELGENE*28CPS 50MG; TIMOLOL MALEATE; Tacrolimus; Tacrolimus (Advagraf); Tacrolimus capsule (low-dose); Tamoxifen; Thalidomide; Timolol; Timolol Alcon 0.5% collyre; Timolol Gel; Timolol nasal spray; Topical timolol maleate; Tranexamic Acid; Tranexamic acid; Vit D

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2009-018049-19-AT (EUCTR)	13/12/2010	23/11/2010	A randomized double blind placebo controlled trial of intranasal submucosal bevacizumab in hereditary hemorrhagic telangiectasia - Bevazizumab in HHT	A randomized double blind placebo controlled trial of intranasal submucosal bevacizumab in hereditary hemorrhagic telangiectasia - Bevazizumab in HHT	epistaxis	Trade Name: AVASTIN 25 mg/ml - Konzentrat zur Herstellung einer Infusionsloesung INN or Proposed INN: BEVACIZUMAB Trade Name: PHYSIOLOGISCHE Kochsalzloesung Fresenius - Infusionsloesung Product Name: PHYSIOLOGISCHE Kochsalzloesung Fresenius - Infusionsloesung Other descriptive name: SODIUM CHLORIDE	Medizinische Universität Wien,Univ.Klinik f.Hals-, Nasen- und Ohrenkrankheiten	NULL	Not Recruiting			Female: yes Male: yes	30		Austria

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

EUCTR2009-018049-19-AT
(EUCTR)

13/12/2010

23/11/2010

A randomized double blind placebo controlled trial of intranasal submucosal bevacizumab in hereditary hemorrhagic telangiectasia - Bevazizumab in HHT

epistaxis

Trade Name: AVASTIN 25 mg/ml - Konzentrat zur Herstellung einer Infusionsloesung
INN or Proposed INN: BEVACIZUMAB
Trade Name: PHYSIOLOGISCHE Kochsalzloesung Fresenius - Infusionsloesung
Product Name: PHYSIOLOGISCHE Kochsalzloesung Fresenius - Infusionsloesung
Other descriptive name: SODIUM CHLORIDE

Medizinische Universität Wien,Univ.Klinik f.Hals-, Nasen- und Ohrenkrankheiten

NULL

Not Recruiting

Female: yes
Male: yes

Austria